AR081991A2 - FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS - Google Patents

FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Info

Publication number
AR081991A2
AR081991A2 ARP110102193A ARP110102193A AR081991A2 AR 081991 A2 AR081991 A2 AR 081991A2 AR P110102193 A ARP110102193 A AR P110102193A AR P110102193 A ARP110102193 A AR P110102193A AR 081991 A2 AR081991 A2 AR 081991A2
Authority
AR
Argentina
Prior art keywords
production
rifaximin
crystallization
rifaximine
processes
Prior art date
Application number
ARP110102193A
Other languages
English (en)
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081991(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of AR081991A2 publication Critical patent/AR081991A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forma cristalina polimórfica del antibiótico rifaximina (INN) denominadas rifaximina b que presenta un contenido de agua mayor que un 4,5% y produce un difractograma de polvo por rayos X que presenta picos en valores de ángulos de difracción 2q de 5,4º; 6,4º; 7,0º; 7,8º; 9,0º; 10,4º; 13,1º; 14,4º; 17,1º; 17,9º; 18,3º; 20,9º. Esta forma es de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un periodo de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final.
ARP110102193A 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS AR081991A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
AR081991A2 true AR081991A2 (es) 2012-10-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Country Status (38)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676848B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE421966T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE04005541T1 (es)
DK (3) DK1676847T3 (es)
ES (3) ES2244364T3 (es)
HK (3) HK1073657A1 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1676848T3 (es)
PT (3) PT1676847E (es)
RS (4) RS20060168A (es)
RU (1) RU2270200C2 (es)
SI (3) SI1676847T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
SI1698630T1 (sl) * 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2008035109A1 (en) * 2006-09-22 2008-03-27 Cipla Limited Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2389358T5 (es) * 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
NZ587099A (en) * 2008-02-25 2012-08-31 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
MX2010009197A (es) 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
CA2723752A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
LT3628319T (lt) * 2008-10-02 2024-03-25 Salix Pharmaceuticals, Inc. Hepatinės encefalopatijos gydymas rifaksiminu
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CN102548408A (zh) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 治疗肝性脑病的方法
ES2712080T3 (es) * 2009-10-27 2019-05-09 Lupin Ltd Dispersión sólida de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) † 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086338A (ko) * 2010-06-03 2013-08-01 샐릭스 파마슈티컬스 리미티드 리팍시민의 신규한 형태들 및 이들의 용도
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MX345697B (es) 2010-07-12 2017-02-13 Salix Pharmaceuticals Ltd Formulaciones de rifaximina y usos de las mismas.
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
EP2672970B1 (en) * 2011-02-11 2018-08-01 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
MX2015014307A (es) 2013-04-12 2015-12-08 Alfa Wassermann Spa Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
AU2017237469B2 (en) 2016-03-24 2018-06-28 Sandoz Ag Storage stable composition comprising rifaximin alpha
WO2017162725A1 (en) 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
MX2018010065A (es) * 2017-04-26 2019-02-07 Sandoz Ag Forma de dosificacion oral que comprende rifaximina en forma beta.
CN110770244A (zh) 2017-06-26 2020-02-07 倍尔福股份公司 吡啶并咪唑利福霉素衍生物的抗菌剂
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3151010A1 (en) 2019-09-24 2021-04-01 Arturo J. Angel Rifaximin liquid formulations
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU1234002A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
WO2008035109A1 (en) 2006-09-22 2008-03-27 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2389358T5 (es) 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
NZ587099A (en) 2008-02-25 2012-08-31 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
EP1682556A2 (en) 2006-07-26
BRPI0402382A (pt) 2005-06-28
RS20150292A1 (en) 2015-10-30
US20050101598A1 (en) 2005-05-12
ITMI20032144A1 (it) 2005-05-08
IL174271A (en) 2010-12-30
CY1108909T1 (el) 2014-07-02
PL1557421T3 (pl) 2007-08-31
ZA200401948B (en) 2004-04-29
EP1557421B1 (en) 2007-05-09
JP5199576B2 (ja) 2013-05-15
CL2004000498A1 (es) 2005-03-11
AU2004200964A1 (en) 2005-05-26
WO2005044823A3 (en) 2005-10-27
PT1557421E (pt) 2007-07-31
ES2244364T1 (es) 2005-12-16
RU2270200C2 (ru) 2006-02-20
WO2005044823A2 (en) 2005-05-19
RS54568B1 (en) 2016-06-30
KR20070113326A (ko) 2007-11-28
IL160798A0 (en) 2004-08-31
KR100867751B1 (ko) 2008-11-10
CN1886408B (zh) 2010-06-09
MA27069A1 (fr) 2004-12-20
HRP20040265A2 (en) 2004-12-31
TWI285107B (en) 2007-08-11
PL1676848T3 (pl) 2009-07-31
BRPI0407149A8 (pt) 2019-01-15
US7045620B2 (en) 2006-05-16
BRPI0407149A (pt) 2006-02-07
DE602004019298D1 (de) 2009-03-19
CN1886408A (zh) 2006-12-27
HK1092151A1 (en) 2007-02-02
KR20070113327A (ko) 2007-11-28
TNSN06069A1 (en) 2007-10-03
SI1676848T1 (sl) 2009-06-30
CA2460384A1 (en) 2005-05-07
RS54571B1 (en) 2016-06-30
EP1676848B1 (en) 2009-01-28
EP2210893A1 (en) 2010-07-28
ATE421966T1 (de) 2009-02-15
CO5560083A1 (es) 2005-09-30
US20080132530A1 (en) 2008-06-05
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20060093B1 (hr) 2015-12-18
AR081992A2 (es) 2012-10-31
PT1676848E (pt) 2009-04-09
EP1676847B1 (en) 2009-01-28
US20050272754A1 (en) 2005-12-08
KR20050043589A (ko) 2005-05-11
ES2320160T4 (es) 2011-03-09
EP1676847A1 (en) 2006-07-05
PL1676847T3 (pl) 2009-07-31
MXPA04002353A (es) 2005-05-11
US20120059023A1 (en) 2012-03-08
DK1676848T3 (da) 2009-05-11
CN1613858A (zh) 2005-05-11
JO2470B1 (en) 2009-01-20
CY1108017T1 (el) 2013-09-04
EP1676848A1 (en) 2006-07-05
TW200515913A (en) 2005-05-16
CN101260115B (zh) 2011-11-23
JP2011046738A (ja) 2011-03-10
TNSN04044A1 (en) 2006-06-01
AR043547A1 (es) 2005-08-03
ES2244364T3 (es) 2007-12-01
US8404704B2 (en) 2013-03-26
AU2004287601B2 (en) 2009-02-26
HRP20060093A2 (en) 2006-05-31
CN101260114A (zh) 2008-09-10
HK1073657A1 (en) 2005-10-14
CN101260114B (zh) 2012-11-28
MD20060080A (en) 2006-11-30
SI1557421T1 (sl) 2007-08-31
DK1557421T3 (da) 2007-09-17
IL174271A0 (en) 2006-08-01
JP2007509904A (ja) 2007-04-19
KR100855084B1 (ko) 2008-08-29
CN101260115A (zh) 2008-09-10
RS20150291A1 (en) 2015-10-30
MXPA06002644A (es) 2006-06-06
ATE421965T1 (de) 2009-02-15
SI1676847T1 (sl) 2009-06-30
DE04005541T1 (de) 2005-12-29
DE602004019296D1 (de) 2009-03-19
CY1108964T1 (el) 2014-07-02
KR100883216B1 (ko) 2009-02-13
US7915275B2 (en) 2011-03-29
ATE361927T1 (de) 2007-06-15
RS20060168A (en) 2008-09-29
JP2005139161A (ja) 2005-06-02
RU2004108953A (ru) 2005-10-27
RS54569B1 (en) 2016-06-30
ME00424B (me) 2011-10-10
PT1676847E (pt) 2009-04-09
UA86384C2 (uk) 2009-04-27
NO20061110L (no) 2006-04-19
JP5635376B2 (ja) 2014-12-03
DE602004006367C5 (de) 2019-04-04
ES2320161T3 (es) 2009-05-19
CA2538546C (en) 2011-04-19
AU2004287601B8 (en) 2009-03-05
DE602004006367T2 (de) 2007-09-06
DE602004006367D1 (de) 2007-06-21
AU2004287601A1 (en) 2005-05-19
JP2014177500A (ja) 2014-09-25
YU24804A (sh) 2006-08-17
KR20060110737A (ko) 2006-10-25
NZ531622A (en) 2004-10-29
HK1092150A1 (en) 2007-02-02
MD3653F2 (en) 2008-07-31
NO334950B1 (no) 2014-08-04
US20110160449A1 (en) 2011-06-30
CA2538546A1 (en) 2005-05-19
JP2011057698A (ja) 2011-03-24
US8173801B2 (en) 2012-05-08
DK1676847T3 (da) 2009-05-11
MD3653G8 (ro) 2016-08-31
EP1557421A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
AR081991A2 (es) FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
TNSN07292A1 (en) New polymorphous forms of rifaximin,processes for their production and use thereof in the medicinal
MY136643A (en) Pyrimidine derivatives for inhibition of cell-proliferation
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
HRP20130026T1 (hr) Kristalni oblik posakonazola
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
TW200745149A (en) Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments
MY178450A (en) Use of polyols to obtain stable polymorphous forms of rifaximin
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
PL1752443T3 (pl) Nowa postać krystaliczna V agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne, które ją zawierają
EP2641897A3 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof
UA94395C2 (ru) Производное изоксазолина и способ его получения
MX2007001267A (es) Derivados de naftiridinas 2,8-disustituidas.
AR074507A1 (es) Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.
HRP20240026T1 (hr) Kruti oblik ribociklib sukcinata
CA2483875A1 (en) 6,11 bicyclic erythromycin derivatives
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
AP2002002679A0 (en) Novel polymorph V of torasemide.
EP1556364A4 (en) ISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES
TW200509889A (en) Aniline derivatives
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HUP0600651A3 (en) 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for their preparation, pharmaceutical compositions containing the same and their use

Legal Events

Date Code Title Description
FC Refusal